Stay updated on Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial
Sign up to get notified when there's something new on the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page.

Latest updates to the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1. The 'Back to Top' link was removed; this is a minor update with no substantive content changes.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of numerous facility names and locations across various countries, while also removing several previously listed locations. Notably, the core content related to the publications and research findings has been expanded.SummaryDifference34%
- Check143 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check150 days agoChange DetectedThe page has been updated to include new information about metastatic non-small cell lung cancer and a new version revision, while significant details about a Phase 3 study and its criteria have been removed.SummaryDifference3%
- Check166 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for January 22, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.2%
Stay in the know with updates to Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Adagrasib vs Docetaxel in KRAS G12C NSCLC Clinical Trial page.